Related Experiment Videos
IIb/IIIa inhibitors in acute myocardial infarction
1Pitié-Salpétrière Hospital, Paris, France.
Insights
New glycoprotein IIb/IIIa receptor antagonists offer potential in treating acute myocardial infarction (AMI) and preventing complications after percutaneous transluminal coronary angioplasty (PTCA). These agents target platelet clots, unlike older treatments that proved ineffective.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Platelets are crucial in acute myocardial infarction (AMI) and post-percutaneous transluminal coronary angioplasty (PTCA) ischemic events.
- Existing treatments like plasminogen activators are limited by prothrombotic effects and failure in PTCA trials.
Purpose of the Study:
- To evaluate the role of novel platelet antagonists in preventing ischemic complications.
- To explore the potential of these antagonists in treating AMI.
Main Methods:
- Focus on platelet membrane glycoprotein IIb/IIIa receptor antagonists.
- Review of clinical evaluations in PTCA and emerging research in AMI.
Main Results:
- Glycoprotein IIb/IIIa antagonists show promise in preventing PTCA-related ischemic complications.
- Development for AMI treatment is in its early stages, with significant therapeutic potential.
Conclusions:
- Glycoprotein IIb/IIIa receptor antagonists represent a promising therapeutic strategy.
- These agents could improve outcomes for AMI patients undergoing primary angioplasty or thrombolysis.
Abstract:
Platelets play a key role both in ischemic complications after percutaneous transluminal coronary angioplasty (PTCA) and in the pathogenesis of acute myocardial infarction (AMI). Until recently, there was no treatment to dissolve the platelet clot. Indeed, the plasminogen activators achieve fibrin lysis but their platelet activating side-effects and their prothrombotic effects led to failure in PTCA trials and to a significant rate of reocclusions in thrombolysis trials. A new class of platelet antagonists directed against the platelet membrane glycoprotein IIb/IIIa receptor has undergone extensive evaluation in the prevention of ischemic complications of PTCA. In contrast, its development in the treatment of AMI is just starting. This class of medications has the potential to improve clinical outcome of AMI treated either with primary angioplasty or with thrombolysis.